(Reuters) - Shares in British American Tobacco BATS.L and Imperial Brands Plc IMB.L rose on Friday after the U.S. health regulator exempted menthol and tobacco from a list of popular e-cigarette flavors that it has banned under new guidelines.
The U.S. Food and Drug Administration on Thursday said e-cigarette makers will be banned from selling pod-based e-cigarette flavors, including fruit, dessert and mint, in the United States from February.
The ban was less stringent than one U.S. President Donald Trump had proposed in September, when he threatened to remove all flavors, including menthol, from all types of e-cigarettes to curb a teenage vaping epidemic.
BAT shares rose as much as 2.5% and were the biggest gainers in the FTSE 100 index .FTSE where many shares were hit by heightened tensions in the Middle East.
Imperial Brands was also among the handful of gainers, with its shares up 1.4%.
Fears of an outright ban led BAT and Imperial to lower their growth forecasts for their U.S. vaping businesses last year.
“Following a significant period of disruption and uncertainty, this regulatory clarity is a welcome step towards returning the U.S. vapor market to stability,” BAT, the maker of Lucky Strike, Dunhill and Vuse e-cigarettes, said on Friday.
The new FDA guidelines would also allow tobacco makers to bring back some of the banned flavors if their marketing applications passed a substantive review by the FDA.
This removed some ambiguity related to the future of the exempted products, Simon Evans, spokesman for Imperial Brands said.
“In addition to exempting menthol, the FDA guidance is clear that flavored products will return to the market once they have been approved through the Premarket Tobacco Product Application (PMTA) process,” he said.
Brokerage Jefferies said that while vaping sales would take a near-term hit from the new rules, the overall financial impact for BAT and Imperial would be minimal as most users would either switch to menthol or tobacco, or even to higher-margin traditional tobacco products.
“We are actually bullish on implications of this final guidance,” Jefferies said.
BAT submitted a marketing application for its Vuse Solo e-cigarette to the FDA in November, while Imperial said it would submit its applications for its Blu e-cigarettes before May.
Reporting by Siddharth Cavale and Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty and Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.